TrialFrontiers in immunology2024

Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study.

Shuang Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.